For US Residents Only

 Hospital ATIII, Hospital antithrombin
Hospital ATIII, Atryn, Anti-clotting, Anticoagulant for a rare disease known as AT (hereditary antithrombin) deficiency, health provider website for Atryn





ATryn is produced through transgenic, recombinant technology—independent of the supply of human plasma, with no preservatives.1


ATryn provides a homogeneous, well-defined, and abundant supply of antithrombin with distinct dosing forumlae.1,2

References: 1. ATryn [package insert]. Framingham, MA: GTC Biotherapeutics; April 2009.
2. Echelard Y, Meade HM, Ziomek CA. The first biopharmaceutical from transgenic animals: ATryn®.
In: Knäblein J, ed. Modern Biopharmaceuticals. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA; 2005;995-1016.

Indications and Usage:
ATryn is a recombinant antithrombin indicated for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients.

It is not indicated for treatment of thromboembolic events in hereditary antithrombin deficient patients.

Important Safety Information:
ATryn is contraindicated in patients with known hypersensitivity to goat and goat milk proteins. Allergic-type hypersensitivity reactions, including anaphylaxis, are possible. Patients must be closely monitored and carefully observed for any symptoms throughout the infusion period. Patients should be informed of the early signs of hypersensitivity reactions including hives, generalized urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis. If these symptoms occur during administration, treatment must be discontinued immediately and emergency treatment should be administered.

The anticoagulant effect of drugs that use antithrombin to exert their anticoagulation may be altered when ATryn is added or withdrawn. To avoid excessive or insufficient anticoagulation, coagulation tests suitable for the anticoagulant used (e.g., aPTT and anti-Factor Xa activity) are to be performed regularly, at close intervals, and in particular in the first hours following the start or withdrawal of ATryn. Additionally, patients should be monitored for the occurrence of bleeding or thrombosis in such situations.

The serious adverse reaction that has been reported in clinical studies is hemorrhage (intra-abdominal, hemarthrosis, and post procedural). The most common adverse events reported in clinical trials at a frequency of ≥5% are hemorrhage and infusion site reaction.

For more information, please download full Prescribing Information for ATryn.

® Trademark of GTC Biotherapeutics, Inc in the United States

You are encouraged to report
negative side effects at
1-800-455-1141 or to the FDA.
or call 1-800-FDA-1088.